Cowen and Company Lowers Versartis, Inc. (VSAR) to Market Perform

Cowen and Company lowered shares of Versartis, Inc. (NASDAQ:VSAR) from an outperform rating to a market perform rating in a research note published on Friday, Marketbeat Ratings reports. They currently have $3.00 price objective on the biopharmaceutical company’s stock, down from their previous price objective of $45.00.

Several other equities research analysts have also recently commented on the company. Piper Jaffray Companies reaffirmed a buy rating and set a $26.00 target price on shares of Versartis in a research note on Friday, September 8th. ValuEngine raised Versartis from a sell rating to a hold rating in a research note on Friday, September 1st. Cantor Fitzgerald set a $34.00 target price on Versartis and gave the stock a buy rating in a research note on Thursday, July 27th. BidaskClub raised Versartis from a hold rating to a buy rating in a research note on Monday, July 24th. Finally, Zacks Investment Research raised Versartis from a sell rating to a hold rating in a research note on Thursday, June 29th. One analyst has rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. The company presently has an average rating of Hold and an average price target of $8.78.

Versartis (VSAR) opened at 2.675 on Friday. The company’s market cap is $95.17 million. The stock’s 50 day moving average price is $18.37 and its 200 day moving average price is $18.36. Versartis has a 12-month low of $2.60 and a 12-month high of $24.00.

Versartis (NASDAQ:VSAR) last issued its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.20). Equities research analysts anticipate that Versartis will post ($3.54) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Cowen and Company Lowers Versartis, Inc. (VSAR) to Market Perform” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at https://sportsperspectives.com/2017/09/25/cowen-and-company-lowers-versartis-inc-vsar-to-market-perform.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in VSAR. Perceptive Advisors LLC boosted its holdings in Versartis by 6.1% in the first quarter. Perceptive Advisors LLC now owns 4,407,317 shares of the biopharmaceutical company’s stock worth $94,096,000 after acquiring an additional 253,632 shares in the last quarter. Driehaus Capital Management LLC bought a new position in Versartis in the first quarter worth approximately $4,117,000. Renaissance Technologies LLC boosted its holdings in Versartis by 334.6% in the first quarter. Renaissance Technologies LLC now owns 214,700 shares of the biopharmaceutical company’s stock worth $4,584,000 after acquiring an additional 165,300 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Versartis by 11.9% in the second quarter. Vanguard Group Inc. now owns 1,121,401 shares of the biopharmaceutical company’s stock worth $19,569,000 after acquiring an additional 118,894 shares in the last quarter. Finally, ClariVest Asset Management LLC bought a new position in Versartis in the first quarter worth approximately $2,480,000. 78.24% of the stock is owned by institutional investors and hedge funds.

About Versartis

Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.

Analyst Recommendations for Versartis (NASDAQ:VSAR)

Receive News & Ratings for Versartis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply